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ABSTRACT 
Objective: Medication adherence is a prominent issue in the general population; therefore, due to the nature of dementia, the risk of medication no 
adherence is even greater. Furthermore, there have been discrepancies regarding the impact of specific determinants on medication adherence as 
previous literature has cited conflicting information. This review aimed to identify the potential causative relationship of dementia that may result 
in medication non-adherence. 
Methods: A meta-analysis of (15 primary research papers) was conducted to identify and assess the specific themes and determinants related to 
non-adherence, and their impact on medication adherence in those who were cognitively impaired.  
Results: Four domains were established or developed upon review and risk of bias and risk of the summary table were created. A critical review 
undertaken to analyse various papers and their respective findings. Through the data analysis it was found that common themes could be established, 
such as Cognitive impairment, Disability, Mental illness and occasional forgetfulness to take their medication. The impact of each domain was expressed 
e. g. the predominant role of executive function and memory as well as non-adherence leading to delusional or suspicious thoughts. 
Conclusion: The findings align with current literature. The caregiver aspect needs to be addressed more thoroughly and more investigations are 
required such as identifying underlying factors that may potentially result in influence.  
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INTRODUCTION 
Adherence can be defined as; “the extent to which a person’s 
medication-taking behaviour, following a diet and/or executing 
lifestyle changes-corresponds with agreed recommendations from a 
healthcare provider” according to the World Health Organisation 
(WHO) [1]. This ultimately suggests that if an individual abides by 
the recommendations that had been set by their healthcare provider, 
they are classed as adherent and if they do not follow those 
recommendations, they are then classed as non-adherent. 
Medication adherence can be important to all the parties involved, 
due to the potential sequalae caused by non-adherence. “No 
adherence may limit the benefits of medicines, resulting in lack of 
improvement, or deterioration, in health “according to the UK 
national institute of clinical excellence (NICE). When patients do not 
disclose or recognise their non-adherence, this can lead to health 
professionals considering their current therapy to be ineffective and 
add new medications or cause the patient to deteriorate causing 
condition complications and hospital admissions. Both situations 
trigger more cost for both the individual and the health system “The 
economic costs are not limited to wasted medicines but also include 
the knock-on costs arising from increased demands for healthcare if 
health deteriorates “as stated by NICE [2]. 
The findings of non-adherence by the WHO (2003) has been further 
explored by Burnier and Egan [3] who stated that some patients may not 
accept the diagnosis while some patients may not understand the 
importance of controlling the severity of their illness which may result in 
a faster decline of their condition. It has been shown4 that around one 
third (33%) of all patients stop taking their medication 10 d after 
initiation of long-term therapy and almost half (50%) of those who do so, 
do it deliberately although their reasons vary. It has shown that only 
16% continue to take their medications as directed. This demonstrates 
the important of addressing adherence going forward [4]. 
“Dementia is a progressive clinical syndrome characterised by a range 
of cognitive and behavioural symptoms that can include memory loss, 
problems with reasoning and communication, a change in personality, 
and a reduced ability to carry out daily activities such as washing or 
dressing” as defined by NICE [2]. 
The term dementia is an umbrella term and consists of Alzheimer’s 
disease, which is the most prevalent type of dementia. Vascular 
dementia (VaD) is the second most common type, affecting around 
150,000 people in the UK. Vascular dementia can be caused by 
strokes and transient ischaemic attacks. Dementia with Lewy bodies 
accounts for 10-15% of all cases of dementia. It occurs where there 
are deposits of alpha-synuclein that appear in nerve cells in the 
brain, however, it is not fully understood how this contributes to 
dementia. 
Front temporal dementia (FTD) usually affects those aged around 45 
to 54 y. This condition is usually caused by the death of nerve cells and 
pathways in the frontal and temporal lobes of the brain. Front 
temporal dementia is commonly associated with other neurological 
impairment such as Parkinson’s disease or motor neurone disease [5]. 
Dementia currently affects approximately 850,000 people in the UK, 
with this fig. expected to rise above 1 million by 2025 and to>2 million 
by 2051. In addition to this, 24.6 million people within the UK are 
aware of a family member or a close friend living with dementia, and 1 
in 3 people within the UK will develop dementia within their lifetime. 
However according to Dementia Statistics Hub (2017)“ due to the 
gradual nature of dementia and the mild early-stage symptoms and 
the low diagnosis rate it is difficult to know the exact number of people 
living with dementia” which suggests that the true value may be 
substantially higher than has been estimated from determining the 
prevalence in different age groups and extrapolating [6]. 
There are stages of dementia, including early dementia in which 
the individual is deemed to be able to still function 
independently; however, these individuals may start to notice 
certain things such as having the inability to recall where they 
may have placed certain objects, experience certain personality 
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changes and struggle to solve complex tasks [5]. Moderate 
dementia is where the individual may experience greater 
memory loss and require assistance with personal activities of 
daily living, such as bathing and dressing. Severe dementia is 
characterised by a loss of the ability to communicate, require full 
time assistance in regarding certain tasks [7]. These stages can 
further be divided into a further seven stages known as the 
functional assessment staging test [8]. 
Dementia can be diagnosed through physical examination, 
neurological examination and mental status tests. These come in 
various forms; the most commonly used is the standardized mini-
mental state examination (SMMSE), which uses a 30-point scale and 
includes questions that examine memory and motor function skills 
[7]. The SMMSE stage-1 consists of repeating certain words back. In 
stage-2 the individual is asked to draw a clock. At stage 3 the 
individual is asked to repeat the words back that were mentioned in 
stage 1. Finally, the healthcare professional who is conducting the 
examination utilises a clinical dementia rating scale where a score of 
0 is normal, a score of 0.5-1 is mild dementia a score of 2 is 
moderate and a score of 3 is severe [9]. 
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
(DSM-V) has stated that there are various cognitive domains involved 
in cognition such as learning, memory, executive functioning, and 
motor ability [10]. The American Psychiatric Association has outlined 
the different domains and their different roles in the makeup of 
cognition. Executive functioning is involved in planning, decision 
making, working memory and responding to feedback. Memory is 
orientated around immediate, recent and long-term memory [10]. 
Therefore, due to the different functions of domains, in theory, the 
symptoms should be specific and applicable to each domain. For 
instance, it had been stated that the memory domain is one of the most 
important regarding medication adherence and administration [11]. 
However, Stoehr et al. [12] had put forward the theory that executive 
functioning plays a more vital role compared to memory regarding 
medication adherence. Similarly, external factors have been associated 
to medication adherence in cognitive impairment such as 
polypharmacy. However, the impact of this factor varied, for instance, 
it had been shown that the number of medications is not a substantial 
factor regarding medication adherence [12]. Although Stoehr found 
that less medication (<5) resulted into greater adherence, this 
discrepancy in relation to the specific determinants that influence 
medication adherence in dementia, requires further investigation to 
ensure that the appropriate interventions can occur. Assessing the 
potential roles determinants play in dementia is crucial in order to 
minimize potential harm. Due to this gap in the knowledge, it is critical 
to further investigate this field and determine the extent to which 
determinants affect medication adherence as well as outline other 
external variables that may potentially influence medication 
adherence in those who are cognitively impaired with a dementia 
diagnosis.  
Aims 
The aim of this critical review was to explore the influence and 




Research identified through databases Library search 
n=1822 
Google scholar n= 1380  
Pub med n= 30 
Science direct n= 68 
Total research paper found n= 4973 
Library search articles that were disregarded 
n=184 after filter applications 6 articles were 
newspaper articles and 3 book chapters were 
excluded. As well as 7 conference 
proceedings and 11 text resources. In 
addition to the subject area being orientated 
and adjusted accordingly. 
PubMed n= 5 articles removed for being 
systematic reviews 
Science direct articles removed due to date 
n= 6 
Articles removed due to being mini reviews, 
practice guidelines, conference abstracts, 
book chapters, encyclopaedia, and “other” 
n=38   
Potentially relevant papers maintained for library search 
n=1638  
Google scholar n=1380 
PubMed n=25 
 Science Direct n=24  
Total Potentially relevant papers maintained for library search 
n= 3067 
Potentially relevant papers maintained in total n=149  
 
Title screening 
Library search Papers excluded due to title screening 
n=1578 
Google scholar Papers excluded n=1300 
PubMed n=20 
Science direct n=19 
Abstract screening  
Papers removed due to abstract analysis for 
reasons such as not pertaining to the concept 
presented in the title n=110  
Potentially relevant papers-maintained n=39 
Full paper Review 
Papers excluded after full analysis n= 24 
Papers maintained for the meta-analysis n=15  
 
Fig. 1: Search strategy 
 
Methods and design 
Search strategy and sample 
A search within ScienceDirect®, PubMed®, Elsevier® and 
Google®Scholarliterature databases, was performed in November 
2019 using a combination of the following terms: <health 
determinants>,<side effect>,<medication adherence>,<cognitive 
impairment>and<Caregivers>(fig. 1). For a study to be included in 
the review, the following inclusion criteria were used:  
1. Primary studies (not a systematic review or meta-analysis). 
2. Full text is accessible. 
Richardson et al. 
Int J Curr Pharm Res, Vol 12, Issue 3, 1-9 
3 
3. Primary outcome is one or all of the following:  
a. One or more cognitive impairment determinants. 
b. Dementia and its effects on medication adherence. 
c. Medication adherence. 
d. Caregivers’ inclusion. 
Randomized control trials were part of the inclusion criteria, 
including studies which used quantitative data/qualitative data. The 
following studies were excluded:  
1. Small sample such as pilot studies. 
2. Non-primary studies e. g. systematic reviews. 
3. Non-English studies. 
Studies dated over 20 y. 
To assess the suitability of articles found via the search strategy; the 
Critical appraisal skills programme (CASP, casp-uk. net) tool was 
used to assess the integrity of the papers to ensure they were 
appropriate (Appendix 1).  
The use of PICO (prisma-statement. org/) facilitated the search of 
similar papers as it allowed work to be orientated within a specific 
spectrum (table 1). 
  
Table 1: The PICO model for clinical questions 
P Patient, Population, or problem Ranges from adults and the elderly 
I Intervention, Prognostic Factor, or Exposure The effect of different domains on medication adherence  
C Comparison or Intervention (if appropriate) Comparison will involve the different domains and external factors that affect 
medication adherence.  
O Outcome you would like to measure or achieve The outcome will revolve around the effects and extent of influences regarding the 
domains and determinants 
  What Type of question are you asking? The extent of influence of determinants on medication adherence. 
  Type of Study you want to find Primary studies will be found to ensure the obtainment of first-hand data.  
 
Regarding population, the studies obtained were mostly looking at 
middle-aged and/or older individuals rather than younger patients 
unless the study had looked at both. Similarly, specific disease states 
or those of similar characteristics e. g. ‘cognition’ were included. 
Interventions included different cognitive domains, determinants of 
cognition, but all included assessment of cognition.  
Fifteen studies were identified and included in this review (table 2). 
 
Table 2: Final papers selected for the systematic review (Columns 2-5 are direct quotations from the published papers) 
Study  Study type Sample  Results  Conclusion  





control study.  
Required to be 50 
years of age and 
have completed 1 of 
2 US Phase and 
required to have had 
a diagnosis of AD. 
Patients randomly assigned 5 mg dose of 
donepezil and placebo began to show 
decline below at week 12. Those randomly 
assigned 10 mg of donepezil began to show 
decline at week 36.  
Sustained treatment may confer some 
advantages. Donepezil found to be an 
effective and safe drug for long term 
treatment for up to 2.8 years for mild 
to moderately sever dementia.  









in two major 
hospital systems 
opportunity sample  
Composite higher attention, executive 
functioning and memory scores were 
associated with greater medication 
adherence. The relationship between 
reduced memory and poorer medication 
adherence remained significant in the 
adjusted analysis (β = 0.51, p =.008) (Table 
3). 
There has been a highlighted 
importance of considering a cognitive 
function in the management of patients 
with HF. Cognitive impairment and 
memory, in particular, is associated 
with with objectively monitored 
medication adherence in patients with 
heart failure.  






with a DSM-IV 
diagnosis of 
schizophrenia who 
were participants in 
the intervention 
research centre for 
psychosis in older 
adults at the 
university of 
California  
Results 1 – found that better scores on the 
dementia rating scale were associated to 
better medication management ability scale. 
DRS Conceptualisation score 0.312** and, 
DRS memory 0.275  
*pV0.05. **pV0.01 
Cognitive functions, especially 
conceptualization and memory, were 
the strongest patient-related 
predictors of his or her ability to 
manage medications, over and above 
the effects of age, gender, education 













support agencies  
Those in profile one achieved a mean 
adherence rate of 0.69 (80% CrI:  0.61–
0.77) 
those in profile 2 achieved of 0.8 (80% CrI:  
0.77–0.84)  
Identified caregiver influence that 
affect medication adherence  
Austin et al. 
(2017) 
Retrospective 
analysis study  
Opportunity sample 
recruited from local 
retirement 
communities for a 
technology study  
Percentage of days where medications were 
missed was not significant at the 0.05 level. 
P=-0.63. The second model found that those 
with a lower cognitive score would have 
more spread in the timing of their 
medication as it was found that for each 
additional minute of spread ppts scored 
Concluded that ppts with higher 
cognitive function are more regular 
with the medication routine. Results 
suggest that early detection of minor 
cognitive impairment can be 
established,  
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0.004 points lower on their cognitive z 
score. P=0.014 






of 137 HIV 
The mean adherence rate was 80.2%. Only 
34% took 95% of their prescribed dose. 
47% of ppts were able to attain 90% of 
adherence rate. Cognitively impaired 
participants had lower adherence rates 
(73%) than the cognitively intact group 
(84%) [F(1,136) = 20.39, p < 0.001]. A main 
effect for regimen complexity was also 
obtained [F(1,136) = 11.12, p = 0.001] 
Unexpectedly, there was a strong 
relationship between older age and 
better adherence patients age 50 and 
older were 2.9 times more likely to 
adhere than were younger subjects 
may be due to ranging and poor 
medication adherence may have 
multiple untoward clinical 








patient aged 65 and 
more, first 
hospitalization of a 
senior due to 




Opportunity sample  
Non-adherence to psychiatric medication 
appeared in 38.1% of all non-adherent 
patients (n = 268). Main primary reason for 
non-adherence was that patient had 
forgotten if the prescribed drug was taken 
or not. Sensory impairment (especially 
visual disturbances) caused non-adherence 
to treatment in 14.2% of non-adherent 
patients  
Non-adherence is great issue in the 
older population in those who suffer 
from dementia and can lead to the 
development of serious side effects and 
wrong therapy of the drug which may 
result into an increase in financial 
expenditure. A higher cognitive decline 
in a patient means a higher risk of non-
adherence to treatment 
Thiruchselvam 




Participants in this 
study were drawn 
from a prospective 
study of 365 
17.4%) had, at least, one report of 
medication nonadherence. Having at least 
one previous occurrence of medication 
nonadherence (OR=2.61; 95%CI=1.18–
5.62) and taking at least four medications 
(OR=2.58;95%CI=1.31–5.29), both 
increased the odds by over 2.5-fold. 
Better conceptualization predicted 
non-adherence. poor memory and 
executive function, taking more than 
four medications, and at least one 
previous occurrence of medication 






Opportunity sample  The prevalence of HF among the sample 
was 15.5%. while MCI was present in 42.3% 
of the sample. Among individuals with MCI, 
having a caregiver at the same residence 
reduced medication non-adherence. 
Additionally, caregiver stress was 
significantly associated with higher rates of 
non-adherence 
Minor cognitive function can impair 
medication adherence and the 
presence of a caregiver is essential in 
the safety of the adult  










The LFC group had poorer performance on 
the ADAS-COG score than the HFC group. 
(HCF:   
6.0 ± 2.1, LCF:  9.9 ± 2.1, t36 = –5.81, p 
<.001). 
very mild cognitive deficits may have a 
profound impact on medication taking, it 
is important that adherence during 
the trial be monitored closely if cognitive 






A volunteer sample 
of 431 HIV-infected 
adult 
executive functioning, motor functioning, 
and processing speed were strongly related 
to adherence in this age group. 
neurocognitive impairment was associated 
with poorer medication adherence among 
older participants only 
Older HIV-positive individuals with 
neurocognitive impairment or drug 
problems are at increased risk of 
suboptimal adherence to medication 





study of a 
population-
based cohort 
Opportunity  patients receiving oral rivastigmine had the 
highest PDC and MPR and had a 
significantly higher PDC compared with 
those receiving rivastigmine patch (P 
<.001). Patients receiving donepezil had a 
significantly higher PDC compared with 
those receiving rivastigmine patch (P 
=.001), whereas no significant difference 
was observed between the oral rivastigmine 











60.8% of participants were considered to be 
sub-optimally adherence 50.3% of 
participants (ppts) forgot to take their 
medication. 28% were being careless about 
taking their medication. 16.8% stopped 
taking medication when they felt better. 
Non-adherent participants had lower scores 
on living with daily activities as well as the 
belief that medicines may be harmful 
established on the BMQ.  
Negative beliefs about medication as 
well as the emotional burden of living 
with another condition i. e diabetes and 
the ability to afford medication were 
related to suboptimal performance.  





Volunteer sample More than one-third of the sample 41% 122 
of 299 reported at least 1 non-adherent 
behavior most common was forgetting to 
take medication; almost 10% of participants 
reported being careless. Older participants 
with a depression diagnosis were less 
adherent than those with no diagnosis 
Results suggest that interventions to 
improve adherence should address 
various obstacles faced by older adults 
Richardson et al. 










Opportunity sample  Pearson correlation analysis showed Total 
Cognition 
Score was positively associated with total 
adherence 
(r ¼ 0.21, p <.01). 
The current study shows that poorer 
performance on cognitive testing is 
predictive of nonadherence in an RCT. 
In addition to being vulnerable to 
worse health outcomes. 
 
Data synthesis and analysis 
Common themes/domains were highlighted throughout these 
papers, which included reasons identified for non-adherence; simply 
forgot, cognitive deficitswhich included sensory impairment as well 
as executive functioning, polypharmacy and the role of caregivers. 
Regarding the theme of the patient/individuals simply forgetting 
their medication, several studies [13, 14, 20, 24, 25] categorised 
them as forgotten to take their medications due to:  
1. Cognitive impairment 
2. Disability 
3. Mental illness 
4. Simplyoccasionally forgetting to take their medication 
Hinkin et al. [13] found that 75 participants believed that they had 
just forgotten to take their medication on several occasions [13]. 
Lužný, et al. [14] found that the primary reason for non-adherence 
was that patients did not know whether they had already taken their 
medication or not. However, this category may have been 
established due to self-reporting, as this was what the patients 
believed was the reason for their non-adherence, when in fact it may 
have been due to a more deep-rooted issue [14]. 
A further domain discussed is the impact of non-adherence in 
worsening cognitive function. Sanborn et al. [15] presented the 
theory of vulnerability becoming more prominent within patients as 
time progressed, in addition to their deteriorating health outcomes 
potentiated by non-adherence [15]. Similarly, Doody [16] 
highlighted the effects of worsening health outcomes from 
nonadherence and the lack of benefit resulting [16]. Lužný, [14] 
further expressed this theme, reporting that persistent non-
adherence could lead to delusional or suspicious thoughts,in which 
the patient may refuse further medication. 
Chang et al. [17] and Hinkin et al. [13] suggested that non-adherence 
may have multiple clinical consequences in addition to cognitive 
decline. Hinkin [13] also stated that being adherent resulted in a 
slower decline of multiple cognitive functional and global outcome 
measures. This theme was developed by Austin et al. [18], who 
suggested that these factors may be due to the increase of duration 
of ongoing medication. This provided a possible explanation and 
insight into a potential cause. The consistent themes identified were 
in relation to cognitive function and its constituents, attention, 
memory, executive functioning and their respective influences. 
It has been shown that executive functioning has a predominant role 
in adherence, for example, Hinkin et al. discussed executive 
functions as a driving force in adherence and that this was apparent 
in previous work [13]. It was further developed by Ettenhofer et al., 
who also highlighted the importance of executive functioning 
through their findings [19]. However, memory and attention were 
not found to be significant in comparison to executive functioning 
and motor functioning. Thiruchselvam et al. [20] discovered poor 
performances on the DRS memory subscales lead to poor adherence, 
which opposed the findings of Ettenhofer et al. [19]. Both studies 
expressed the importance of executive functioning and its effects. 
Conversely, Hayes et al. (2009) found that the impact of memory 
planning and executive functioning were not as great as suggested in 
other studies [21]. This may imply that the extent or methodology in 
the use of tests may account for the differences in the effects of the 
different domains.  
External factors regarding personal beliefs and co-morbidity were a 
further theme/domain highlighted. Ettenhofer, Rovner and Casten 
and Sirey et al. advanced the idea of co-morbidity affecting 
adherence [19, 22, 23]. For instance, Rovner found that the burden 
of living with more than one condition, which individually can 
worsen daily functioning, resulted into sub-optimal adherence [22]. 
They suggest that stressors of another condition can inadvertently 
affect adherence. In addition to this Rovner, Sireyand Thiruchselvam 
et al. also expressed that health beliefs about medication is a further 
theme [22, 23, 20]. Thiruchselvamdiscovered that patients who 
scored high on the dementia rating scale (DRS), a conceptualization 
subscale were found to be non-adherent [20]. This was attributed to 
the idea of concerns about their medication. Likewise, Rovner and 
Sireyfurther supported the idea of health beliefs potentially affecting 
adherence in cognitively impaired patients [22, 20]. 
Polypharmacy was considered a new theme, but the findings were 
more controversial. Dolansky et al. stated there was no significant 
relationship between the number of medications and the complexity 
of the regimen on medication adherence; however, it could be due to 
the complexity of medication being self-reported [24]. Comparably, 
Hayes found that polypharmacy had some effect, but the effect was 
not significant [21]. Thiruchselvam found taking more than 4 
medications increased medication non-adherence by over 2.5-fold 
[20]. Austin et al. discussed the potential for polypharmacy to affect 
medication adherence; however, this was only indicated and not 
explicitly stated [18]. 
To add to this, caregivers were mentioned in few studies. For instance, 
Foebel, highlighted the fact that potential stressors can affect the 
caregiver, which then may result into non-adherence [25]. Similarly, 
Lužný, was the only researcher to examine this in depth [14]. 
Level of bias 
The attainment of the graphs (fig. 3 and 4) below were developed 
using RevMan 5®. Within the application, a table was made for each 
separate paper. The table contained the domains present on the 
graph below in addition to the authors judgment and the support for 
judgment. CASP forms were completed as part of the process and the 
support for each judgment was given. This allowed the use of the 
labels “Low risk”, “Unclear risk,” and “Highest risk” for each study 
pertaining to each domain. Which resulted in the risk of bias and 
summary of bias graphs presented below. 
  
 
 Fig. 2: Risk of bias presented as percentages across all included studies 
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Fig. 3: Risk of bias summary 
 
The effect of the depression domain within this study was debatable 
as the confidence interval had been placed in question. Executive 
functioning, memory and social support (caregiver) had a larger 
effect size and the confidence intervals were more reliable in 
comparison to depression (fig. 4). 
Hinkin reported that the age group component had longest 
horizontal line, which indicates a lack of reliability in comparison to 
the rest of the factors that had been displayed [13]. Regimen 
complexity, psychiatric history, neurologic history and global 
neuropsychological impairment had more of a reliable effect (fig. 5). 
  
 
Fig. 4: Cognitive domains 
 
 
Fig. 5: Factors affecting adherence 
 
 
Fig. 6: Factors affecting adherence 
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With respect to Thiruchselvam it had been shown that 
conceptualisation, memory, attention all had a significant impact on 
adherence furthermore, it had been clearly displayed that the results 
were reliable whereas polypharmacy had been questioned due to 
the wide confidence intervals (fig. 6) [20]. 
Critical review 
It has been suggested that various cognitive domains may heavily 
influence medication no adherence. According to Smith et al. the 
“development of tailored interventions to combat non-adherence 
requires a better understanding of the potential contribution of 
cognitive domains” [26]. To truly understand the way in which 
cognitive impairment affects medication adherence, focus must be 
placed upon all present domains, to understand the impact each 
domain hason each other and on medication adherence. This study 
has shed light on the idea that the focus of studies to date is 
orientated upon two compartments which in this case is memory 
and executive functioning. Jeste et al. pointed that cognitive function 
was a significant predictor of medication management but did not 
fail to acknowledge other influencers [27]. In addition, Hinkin found 
that cognitively impaired patients on complex regimes had even 
greater difficulty adhering to medication. Suggesting that simplicity 
is crucial to try and achieve the best outcome [13]. 
It was found in all studies that no adherence can be predicted by the 
diagnosis of deficits in attention/mental flexibility and/or working 
memory [28]. Providing evidence to show other domains are 
associated. The authors also stated that impaired executive function 
was associated with poor adherence in one study out of the three. 
Looking into memory and executive functioning it had also been 
found memory composite score did not predict adherence. This led 
to the suggestion that is likely to be more critical in less educated 
patients [29]. This may provide an explanation for the different 
results achieved by the various studies. The reason why executive 
functioning is examined thoroughly is because evidence has been 
shown that executive function is instrumental to medication 
adherence in addition to the daily activities that are carried out by 
the person [26]. However, this is not black and white since other 
studies have also shown that memory is substantially more 
important [24]. 
Additionally, it has been suggested that medication adherence in 
those who have dementia can be influenced by viainter and 
intrapersonal factors. Arlt, et al.(2008) stated they may be a reason 
why individuals with dysfunctional executive and memory 
functioning may not adhere to their medication due to these factors, 
which may have resulted from previous experiences.[30]This 
highlights the importance of this as it correlates with the caregiver 
due to the nature of cognitive decline, in disease progression. This 
study clearly placed importance of caregivers as responsible to 
ensure that the specified patient takes their medication. Accordingly, 
these intra and interpersonal factors evidently apply to the 
caregivers as well as patients. This was recently presented by El-
Saifi et al. [31]. Who conducted a survey of 320 caregivers to 
determine influencers of medication adherence this study found that 
lower cognitive function of caregivers was a pivotal characteristic in 
the lower adherence group [31]. In a separate study El-Saifi et al. 
[32] stated that non-adherence may arise due to dementia patients 
displaying resistance which cements the importance of inter and 
intrapersonal factors [32]. 
Doody (2001) discussed the progressive cognitive decline in non-
adherence, “After the 6-week placebo washout, the benefits of 24 w of 
treatment with donepezil on cognition and global function were 
completely lost” which clearly establishes the link between 
medication adherence and prolonged cognitive function patients 
[16]. This shows that no adherence can potentially hasa knock-on 
effects as also by Lužný [14]. 
Several studies do not agree with Doody [16]. Maxwell et al. stated 
that there is uncertainty about the time when dementia medication 
should be discontinued because of a perceived lack of clinical benefit 
[33]. This statement highlights the idea of medication adherence 
being potentially detrimental in the long run as the patients do not 
experience alleviation regarding their clinical symptoms, which 
therefore suggests that they may be experiencing side effects. 
Furthermore, there is also the argument which is centred on the idea 
dementia medication ceases slowing down cognitive function at a 
certain point. Maxwell et al. found that patients were hospitalised 
with bradycardia whilst taking cholinesterase inhibitors which 
further stresses the idea of the dangers that may persist if benefits 
do not outweigh the risk [33]. This study ultimately discussed the 
dangers of the continuation of dementia medications, which most 
studies do not address or place focus upon. Further research is 
required to determine when it is appropriate to withdraw the 
medication. Furthermore, the continuation of active treatment may 
lead to hospitalisation and unnecessary cost. 
Austin found that patients with mild cognitive impairment expected 
to take medication for longer time than those with severe symptoms, 
indicating that these patients will not be as adherent or consistent 
long term [18]. However, this study mostly used Caucasians hence 
lacking generalisability as it may not be applied to other ethnicitiess. 
Similarly, Elliott et al. concluded “that impaired cognition affects 
people’s ability to manage regimes and increases the risk of errors 
”this coincides with the idea that decreasing cognitive function has a 
substantial impact on medication adherence [34]. Hawkins et al. 
made similar findings on a specific subpopulation [35]. Similarly, 38 
participants who were ages 65 y were placed into groups and it was 
found that a slight cognitive deficit led resulted into substantial 
impact in medication-taking [21]. 
Unlike other studies a link is made between the severity of dementia 
affecting medication adherence including an explanation for each 
stage, for instance in the early stages of the 57 participants 
interviewed dementia was characterised by resistance to maintain 
independence whereas in the later stages it is due to paranoia [35, 36]. 
This alludes to the idea of a change in medicine management due to 
a change in behavioural patterns. This was further supported by Lim 
and Sharmeen who found that the difficulties of regimens increase 
with dementia progression due to a lack of internal memory cues 
[37]. Furthermore, regarding adherence most studies have looked at 
the concept that medication adherence decreases as the severity of 
dementia progresses. However, it has been suggested that the 
relationship between the two variables may be a U-shaped curve, 
where those with severe dementia rely on caregivers and those with 
mild dementia manage their medication on their own which results 
in increasing errors [38]. However, this topic has not been fully 
investigated and many outlying variables confound the results. A 
further confounder is that many of the studies are dated as most 
studies are dated as far back as 1994.  
DISCUSSION 
The risk of bias regarding the different criteria selected varied, for 
instance; the potential effects of cognitive domains (sensory 
executive functioning and memory) had been outlined in most 
studies, but unclear definitions increase the risk of bias. This was 
attributed to either the researchers touching upon the subject but 
not explaining how it may have affected the study or the potential 
implications. Rovner and Casten acknowledged this but did not 
discuss this aspect thoroughly and instead placed more importance 
on the modifiable determinants of adherence such as daily 
functioning distress and affordability [22]. It was further 
acknowledged through the aspect of daily functioning, as this will 
involve abilities such as organisation planning and the ability to 
multitask, which are essential constituents of executive functioning. 
Therefore, inability to carry out these actions would suggest a deficit 
in the executive functioning domain. This, however, was not 
expressed and only indirectly implied, which led to the unclear risk 
of bias. Similarly, Austin et al. looked at cognitive function 
holistically but did not further digress into the potential importance 
of different domains and respective influences [18]. This is why the 
risk of bias was unclear. 
When looking at the caregiver criteria this had the highest risk of 
bias in comparison to the rest of the comparators. This was mainly 
attributed to the fact that majority of the studies did not cover the 
potential influences or determinants that can affect caregivers or 
acknowledged caregivers as a determinant. This led to high risk 
associated within this domain due to the lack of ground covered. 
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Three studies: Thiruchselvam, Lužný and Dolanskyhad the lowest 
risk of bias compared to others, as they outlined and expressed the 
significance of each domain [20, 14, 24]. For instance, the 
importance of memory was highlighted as a direct relationship 
between medication adherence and cognitive function. This was 
established once covariates were adjusted for Dolansky [24]. 
Similarly, executive function was associated with greater medication 
adherence however, once covariates were adjusted for the 
relationship was said not to be significant. The importance of 
caregivers was highlighted including the positive impact they have 
on medication adherence. Lužnýexpressed the importance of the 
memory domain in relation to medication adherence [14]. This was 
themost commonly expressed factor for non-adherencein addition 
to this the caregiver aspect was also established and the importance 
identified to medication adherence. It was also apparent for 
polypharmacy in all three reports. Ultimately this was significant as 
thorough identification occurred of certain determinants and 
medication adherence whilst also proposing explanations for 
possible causes. Hence the reason for the lowest risk of bias shared 
between all three studies.  
Regarding bias, four studies had a low risk of bias as 75% of the 
domain’s polypharmacy, simply forgetting, executive functioning, 
memory and sensory impairment criteria [19, 21, 13, 23]. Ettenhofer 
found that executive functioning was related to medication 
adherence in the elderly who were cognitively impaired; however 
the same did not apply to the younger group as there wasn’t a 
relationship between cognition and adherence [19]. Whereas 
memory was found to not be significant in relation to adherence in 
older individuals and younger individuals. Similarly, the ideology of 
polypharmacy was touched upon and its influences discussed e. g. 
polypharmacy’s the negative effect on the younger population. 
However, the caregiver domain was not touched, or its effects 
explained. Likewise, Hayes also expressed the importance of the 
three domains in a similar fashion and the importance of executive 
function; however, the caregiver aspect was not expressed [19]. This 
was also apparent for Hinkin, which is why in comparison to the 
three studies the low risk was slightly higher at 75%, due to 
omissions of the caregiver aspect which is an influential factor in 
relation to medication adherence; providing an explanation for the 
rise in bias [35]. To expand, El-Saifi, had a similar risk of bias 
however, the caregiver domain had been thoroughly discussed and 
its effects explained [32]. 
Doody exhibited the highest risk of bias in comparison to the rest of 
the studies [16]. This may have been because of the nature of the 
study and participants taking part; for instance it is difficult to 
establish certain ideology/characteristics with randomised controls 
when looking at dementia patients. As this is a sensitive population, 
the use of cohort/prospective studies and those of a similar nature 
may be more applicable as more information can be obtained. In 
addition the nature of the Doody study was to look at the effects of 
the medication in that “specific population” which meant that a 
cause and effect relationship was the main factor that could have 
been drawn or taken away rather than the domains which may been 
inadvertently affected by the diminished cognition [16]. This 
explained the high risk of bias as none of the domains were touched 
upon or explained, only the establishment of the effects of 
medication adherence on cognition.  
CONCLUSION  
Overall, it may be concluded that the relationship between the levels 
of dementia prognosis (cognitive impairment) and medication 
adherence exist and that mental illness such as depression can add 
further complications. However, the study acknowledges that the 
caregiver involvement in the research needs to be addressed more 
appropriately in future research due to the high level of bias that 
was apparent within this study. More investigations are needed to 
identifying underlying factors that may potentially influence the 
level of adherence to therapy such as extrinsic and intrinsic factors. 
When looking at the different domains such as executive functioning, 
memory, attention and sensory impairment there was a slight 
variation regarding determinants and their respective influences 
especially around memory. 
There were various discrepancies around this aspect, however, upon 
assessment, it is likely that variation can be attributed to the disease 
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